Publications

2024 Publications

Alimujiang A, Strecher V, McLean K, Mondul AM, Pearce CL, Mukherjee B. Decomposing the association of psychosocial wellbeing with all-cause mortality: the mediating role of physical health and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol. 2024 Jul 23. doi: 10.1007/s00127-024-02717-y. Epub ahead of print. PMID: 39044017.

Nagle CM, Ibiebele TI, Bandera EV, Cramer D, Doherty JA, Giles GG, Goodman MT, Hanley GE, Harris HR, Jensen A, Kjaer SK, Lee AW, Milne RL, Qin B, Richardson J, Sasamoto N, Sieh W, Terry KL, Titus L, Trabert B, Wentzensen N, Wu AH, Berchuck A, Pike M, Pearce CL, Webb PM. Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer. 2024 Oct;131(6):1043-1049. doi: 10.1038/s41416-024-02792-7. Epub 2024 Jul 18. PMID: 39026080; PMCID: PMC11405517.

Salvatore M, Kundu R, Shi X, Friese CR, Lee S, Fritsche LG, Mondul AM, Hanauer D, Pearce CL, Mukherjee B. To weight or not to weight? The effect of selection bias in 3 large electronic health record-linked biobanks and recommendations for practice. J Am Med Inform Assoc. 2024 Jun 20;31(7):1479-1492. doi: 10.1093/jamia/ocae098. PMID: 38742457; PMCID: PMC11187425.

Khoja L, Torres HG, Hak L, Aljebori M, Phung MT, Sakleh A, Stiffler M, Tariq M, Pearce CL. Cervical cancer screening and vaccination acceptability and attitudes among Arab American women in Southeastern Michigan: a qualitative study. Sci Rep. 2024 Jun 13;14(1):13624. doi: 10.1038/s41598-024-64462-1. PMID: 38871762; PMCID: PMC11176183.

Dareng EO, Coetzee SG, Tyrer JP, Peng PC, Rosenow W, Chen S, Davis BD, Dezem FS, Seo JH, Nameki R, Reyes AL, Aben KKH, Anton-Culver H, Antonenkova NN, Aravantinos G, Bandera EV, Beane Freeman LE, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bolton KL, Brenton JD, Budzilowska A, Butzow R, Cai H, Campbell I, Cannioto R, Chang-Claude J, Chanock SJ, Chen K, Chenevix-Trench G; AOCS Group; Chiew YE, Cook LS, DeFazio A, Dennis J, Doherty JA, Dörk T, du Bois A, Dürst M, Eccles DM, Ene G, Fasching PA, Flanagan JM, Fortner RT, Fostira F, Gentry-Maharaj A, Giles GG, Goodman MT, Gronwald J, Haiman CA, Håkansson N, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Huang RY, Jensen A, Jones ME, Kang D, Karlan BY, Karnezis AN, Kelemen LE, Kennedy CJ, Khusnutdinova EK, Kiemeney LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Larson MC, Le ND, Lester J, Li L, Lubiński J, Lush M, Marks JR, Matsuo K, May T, McLaughlin JR, McNeish IA, Menon U, Missmer S, Modugno F, Moffitt M, Monteiro AN, Moysich KB, Narod SA, Nguyen-Dumont T, Odunsi K, Olsson H, Onland-Moret NC, Park SK, Pejovic T, Permuth JB, Piskorz A, Prokofyeva D, Riggan MJ, Risch HA, Rodríguez-Antona C, Rossing MA, Sandler DP, Setiawan VW, Shan K, Song H, Southey MC, Steed H, Sutphen R, Swerdlow AJ, Teo SH, Terry KL, Thompson PJ, Vestrheim Thomsen LC, Titus L, Trabert B, Travis R, Tworoger SS, Valen E, Van Nieuwenhuysen E, Edwards DV, Vierkant RA, Webb PM; OPAL Study Group; Weinberg CR, Weise RM, Wentzensen N, White E, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zeinomar N, Zheng W, Ziogas A, Berchuck A, Goode EL, Huntsman DG, Pearce CL, Ramus SJ, Sellers TA; Ovarian Cancer Association Consortium (OCAC); Freedman ML, Lawrenson K, Schildkraut JM, Hazelett D, Plummer JT, Kar S, Jones MR, Pharoah PDP, Gayther SA. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions. Am J Hum Genet. 2024 Jun 6;111(6):1061-1083. doi: 10.1016/j.ajhg.2024.04.011. Epub 2024 May 8. PMID: 38723632; PMCID: PMC11179261.

Meagher NS, White KK, Wilkens LR, Bandera EV, Berchuck A, Carney ME, Cramer DW, Cushing-Haugen KL, Jordan S, Kaufmann SH, Le ND, Pike MC, Riggan M, Qin B, Rothstein JH, Titus L, Winham SJ, Anton-Culver H, Doherty JA, Goode EL, Pearce CL, Risch HA, Webb PM, Cook LS, Goodman MT, Harris HR, Le Marchand L, McGuire V, Pharoah PDP, Sarink D, Schildkraut JM, Sieh W, Terry KL, Thompson PJ, Whittemore AS, Wu AH, Peres LC, Merritt MA. Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium. Am J Epidemiol. 2024 Sep 3;193(9):1242-1252. doi: 10.1093/aje/kwae076. PMID: 38775277; PMCID: PMC11369223.

Khoja L, Wang Y, Haque SE, Ahsan H, Islam T, Munshi SU, Hasan AKMR, Islam MT, Jharna AB, Pearce CL. Understanding of cervical cancer, acceptability of HPV self-collection, and prevalence of HPV in a semi-urban setting in Bangladesh. PLOS Glob Public Health. 2024 Apr 24;4(4):e0003157. doi: 10.1371/journal.pgph.0003157. PMID: 38656991; PMCID: PMC11042693.

2023 Publications

Heinze K, Cairns ES, Thornton S, et al. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas. Clin Cancer Res. 2023 Sep 1;29(17):3471-3483. doi: 10.1158/1078-0432.CCR-22-3815

Kang EY, Weir A, Meagher NS, et al. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. Cancer. 2023 Mar 1;129(5):697-713. doi: 10.1002/cncr.34582

2022 Publications

Meagher NS, Hamilton P, Milne K, et al. Profiling the immune landscape in mucinous ovarian carcinoma. Gynecol Oncol. 2023;168:23-31. doi:10.1016/j.ygyno.2022.10.022

Garsed DW, Pandey A, Fereday S, et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat Genet. 2022;54(12):1853-1864. doi:10.1038/s41588-022-01230-9

Phung MT, Webb PM, DeFazio A, et al. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecol Oncol. 2023;168:68-75. doi:10.1016/j.ygyno.2022.10.018

Phung MT, Alimujiang A, Berchuck A, et al. Reproductive Factors Do Not Influence Survival with Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(4):909-913. doi:10.1158/1055-9965.EPI-21-1091

2021 Publications

Brieger KK, Phung MT, Mukherjee B, et al. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2022;31(2):443-452. doi:10.1158/1055-9965.EPI-21-0977

Hanley GE, Kaur P, Berchuck A, et al. Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada. Gynecol Oncol. 2021;162(2):461-468. doi:10.1016/j.ygyno.2021.05.021

2020 Publications

Saner FAM, Herschtal A, Nelson BH, et al. Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nat Rev Cancer. 2019;19(6):339-348. doi:10.1038/s41568-019-0145-5

Millstein J, Budden T, Goode EL, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020;31(9):1240-1250. doi:10.1016/j.annonc.2020.05.019

Brieger KK, Peterson S, Lee AW, et al. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecol Oncol. 2020;158(3):702-709. doi:10.1016/j.ygyno.2020.06.481

2019 Publications

Minlikeeva AN, Cannioto R, Jensen A, et al. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes Control. 2019;30(5):537-547. doi:10.1007/s10552-019-01157-3

Clarke CL, Kushi LH, Chubak J, et al. Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2019;28(5):996-999. doi:10.1158/1055-9965.EPI-18-1324

Alimujiang A, Khoja L, Wiensch A, et al. "I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival. Gynecol Oncol. 2019;155(3):461-467. doi:10.1016/j.ygyno.2019.10.007

2017 Publications

Praestegaard C, Jensen A, Jensen SM, et al. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. Int J Cancer. 2017;140(11):2422-2435. doi:10.1002/ijc.30600

Dixon SC, Nagle CM, Wentzensen N, et al. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. Br J Cancer. 2017;116(9):1223-1228. doi:10.1038/bjc.2017.68

Minlikeeva AN, Freudenheim JL, Eng KH, et al. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2017;26(9):1470-1473. doi:10.1158/1055-9965.EPI-17-0367

Epidemiology Working Group Steering Committee, Ovarian Cancer Association Consortium Members of the EWG SC, in alphabetical order:, Doherty JA, Jensen A, et al. Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. J Natl Cancer Inst. 2017;109(10):djx144. doi:10.1093/jnci/djx144

2016 Publications

Cannioto RA, LaMonte MJ, Kelemen LE, et al. Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. Br J Cancer. 2016;115(1):95-101. doi:10.1038/bjc.2016.153

2015 Publications

Nagle CM, Dixon SC, Jensen A, et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer. 2015;113(5):817-826. doi:10.1038/bjc.2015.245